Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
22,662 people get PFE articles and Market Currents by email alert.
Get email alerts on PFE »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Pfizer's CEO Discusses Q3 2012 Results - Earnings Call TranscriptThu, Nov 1, 2012 • 1 Comment
-
Pfizer's CEO Discusses Q2 2012 Results - Earnings Call TranscriptTue, Jul 31, 2012 • 2 Comments
-
Pfizer's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, May 1, 2012
-
Pfizer's CEO Hosts 2012 Annual Meeting (Transcript)Thu, Apr 26, 2012 • 2 Comments
-
Pfizer's CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Jan 31, 2012 • 1 Comment
-
Pfizer's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, Nov 1, 2011
-
Pfizer's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Aug 2, 2011
-
Pfizer's CEO Discusses Q1 2011 Results - Earnings Call TranscriptTue, May 3, 2011 • 1 Comment
-
Pfizer's CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 1, 2011 • 1 Comment
-
Pfizer CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Nov 2, 2010
-
Pfizer Q2 2010 Earnings Call TranscriptTue, Aug 3, 2010
-
Pfizer Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Pfizer Inc. Q4 2009 Earnings Call TranscriptWed, Feb 3, 2010
-
Pfizer, Inc. Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
Pfizer Inc. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
Pfizer Q1 2009 Earnings Call TranscriptTue, Apr 28, 2009
-
Pfizer Q4 2008 Earnings and Conference Call TranscriptWed, Jan 28, 2009
-
at MarketWatch.com (May 10, 2013)
-
Business Wire (May 8, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 2, 2013)
-
at Fox Business (May 2, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at Fox Business (Apr 30, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at MarketWatch.com (Apr 30, 2013)
PFE vs. ETF Alternatives
Company Description
Pfizer Inc. (which may be referred to as Pfizer, the Company, we, us or our) is a research-based, global biopharmaceutical company. We apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, April 12, 4:48 PM SAC Capital is reportedly being sued by Wyeth investors over insider trading, just one month after it settled with federal regulators for over $600M under similar allegations. SAC came under fire last year as former fund manager Mathew Martoma was charged with illegally obtaining results from an Alzheimer's drug trial being conducted by Wyeth (now part of Pfizer (PFE)) and Elan (ELN), then trading on the information before the data was made public. Comment! [Financials, Healthcare]
- Wednesday, April 10, 1:37 PM Jefferies raises its price targets on big pharma names Pfizer (PFE +2.6%) ($33), Merck (MRK +2.7%) ($48), Johnson & Johnson (JNJ +0.7%) ($85), Eli Lilly (LLY +1.4%) ($44), Bristol-Myers Squibb (BMY +0.5%) ($45), AbbVie (ABBV +1.2%) ($50), and Abbot Laboratories (ABT +1.1%) ($42). "We remain positive on pharmaceuticals," Jefferies says, "valuation is attractive for most stocks." 6 Comments [Healthcare]
- Wednesday, April 10, 8:23 AM Pfizer (PFE) says it has received Breakthrough Therapy designation from the FDA for the investigational breast cancer treatment palbociclib. The designation will speed development and review of the drug which is in Phase 3 clinical testing. Shares +0.62% premarket. Comment! [Healthcare]
- Thursday, April 4, 5:31 PM Acura Pharmaceuticals (ACUR) has been awarded a patent by the USPTO relating to its Aversion polymer matrix technology when utilized with any water soluble drug of abuse, as well as certain opioid products being developed by the company. Certain claims in this patent are licensed to Pfizer (PFE) which utilizes the Aversion technology in its Oxecta tablets. Comment! [Healthcare]
- Thursday, April 4, 9:56 AM While Pfizer (PFE +1.2%) has spun off its animal-health unit and sold its infant-nutrition business over the past year, it "absolutely" plans to keep its $3.2B/year consumer-health ops, CEO Ian Read has told investors. Read reckons that the unit is critical for Pfizer to take advantage of a growing trend in which prescription drugs gain over-the-counter status. 3 Comments [Healthcare]
- Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
- Wednesday, April 3, 11:08 PM Pfizer (PFE) lost a bid to overturn a ruling awarding Kaiser Foundation Health Plan $142M in connection with the marketing and prescribing of Neurontin for conditions other than those the drug was approved to treat. The court also resurrected claims from other plaintiffs. 2 Comments [Healthcare]
- Wednesday, April 3, 8:26 AM Pfizer (PFE) has agreed to pay closely held Bind Therapeutics up to $210M to use the latter's nanotechnology to develop medicines. Bind's nanoparticles, called Accurins, can transport drugs through the body and home in on diseased cells without harming healthy tissue. Bind's technology has the potential to be used to treat cancer, inflammatory ailments and cardiovascular disorders. (PR) Comment! [Healthcare]
- Tuesday, April 2, 7:05 PM Citi strategists tweak the criteria for their top dividend-paying stock picks, lowering the standard for dividend yield while adding a new filter for dividend momentum “to give more emphasis on dividend safety and growth." The full list: MO, AEP, T, AVB, BMY, ED, D, DD, DUK, INTC, KMB, KRFT, LLY, MCD, MRK, MSFT, NU, NOC, OXY, PFE, PM, RTN, SRE, SO, SYY, XEL. 5 Comments [Quick Ideas]
- Tuesday, April 2, 4:12 PM Pfizer (PFE), Abbott Labs (ABT) and Novartis (NVS) are preparing to enter second-round bids for for Brazil's Ache Laboratorios Farmaceuticos in an auction that may value the group at over $5B. The bids are due in the second half of April, but divisions among certain families controlling the company still remain, fomenting uncertainty as to whether the deal will go ahead. Comment! [Healthcare, Global & FX]
- Thursday, March 28, 5:21 PM Bacteria that live in the gut change after gastric-bypass surgery and may aid in weight loss, according to a recent study. Gastric surgery helps people lose weight by shrinking the size of the stomach and making it tougher to absorb calories, now scientists think it may also adjust gastrointestinal bacteria, contributing to weight loss and raising the possibility for less-drastic obesity treatment. 7 Comments [Healthcare]
- Wednesday, March 27, 3:08 PM Amgen (AMGN +1%) and Johnson & Johnson (JNJ +0.5%) also hit new 52-week highs today on the back of developments stemming from Kinmed and PFE's non-exclusive partnership. Comment! [Healthcare]
- Wednesday, March 27, 2:41 PM Shares of Pfizer (PFE +0.9%) hit a 52-week high earlier today after it announced the renewal of its non-exclusive research collaboration with KineMed. Under the the terms of the agreement, KineMed and PFE will collaborate on the advancement of novel approaches towards the treatment of Type II Diabetes. 1 Comment [Healthcare]
- Monday, March 18, 3:22 PM Protalix BioTherapeutics (PLX +2.3%) reverses morning losses to gain on news that Brazilian health authorities had given regulatory approval to Uplyso, a long-term enzyme replacement therapy for adults with Type I Gaucher disease. PLX has partnered with Pfizer (PFE +0.3%) to market and commercialise the drug worldwide, apart from Israel where it maintains exclusive rights. Comment! [Healthcare, On the Move, Global & FX]
- Wednesday, March 13, 8:09 AM The FDA yesterday intensified its warnings for azithromycin, an antibiotic that can lead to a fatal irregular heart rhythm in some users. Known as "Z-Pack," the drug is used to treat bronchitis, pneumonia, sore throats and earaches. A major manufacturer of azithromycin is Pfizer (PFE). 2 Comments [Healthcare]
- Tuesday, March 12, 10:39 AM The FDA says the antibiotic azithromycin, sold as Zithromax by Pfizer (PFE -0.5%) as well as by others in generic form, can cause a potentially fatal irregular heart rhythm. Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias. 3 Comments [Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
Joseph P. Porter
$PFE defies "whisper" rate and posts lower figures for Q1. Paying the price for it today - down > 3%. Great buying opportunity. - View all 0 replies
-
- View all 0 replies
-
Joseph P. Porter
$PFE had some bad news last week. Long term, though, it is a strong, if cautious, growth with nice divvie on the side. - View all 0 replies
-
Dividend Sheet
$T $INTC $VZ are the best yielding dogs of the dow jones -- http://stks.co/jT3S - 10 shares with 3.53% average yield $DD $CSCO $GE $PFE - View all 0 replies
-
- View all 1 replies
-
-
- View all 5 replies
-
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth. -
-
Joseph P. Porter
$PFE pfaithfully pfollows its tradition of offering its divs - $0.24 to be paid in June. Pfar out. - View all 3 replies
-
Joseph P. Porter: Absolutely pfabulous, in my book. Pfizer is to dividends what prunes are to BM's - regularity exemplified. $PFE is pfar and away the best
-
Joseph P. Porter: company I have shares in. So pfar, more than 30% return, not counting divs. Pfortunately, I bought in over a year ago.
-
Red Acre Investments
Take our poll about $PFE and Remoxy $DRRX and $PTIE investors too! http://bit.ly/14k2VHo - View all 0 replies
LATEST REPLIES
-
- View all 4 replies
-
Hillbilly Stock Star: Hugh Hefner eats viagra like "breath mints on prom night"! To Keep up with new wife! -
Joseph P. Porter: Ah, should have guessed. As long as I get the divs, he can do the Viagra, and more power to him. Thanks for filling me in.
-
Brian L. Wilson
Anyone interested in what $PFE is up to, check out my article on $HALO http://seekingalpha.com/a/nnff - View all 2 replies
-
-
-
- View all 3 replies
-
-
-
- View all 2 replies
-
-
-
- View all 29 replies
-
Mercy Jimenez: DAG UR probably right + better at overcoming this resistance than I am; no doubt I've missed opportunities waiting for meltdowns to pounce. -
DAG1996: i'm often not cautious enough so missing an opportunity is a high-quality problem relative to misinterpreting risk as opportunity.
-
Mercy Jimenez
Booking gains 2keep ave. high cash position; sold PFE, FLY, and TSM; still like all; plan 2buy back if/when @ $24+, $12+, $14+ respectively. - View all 13 replies
-
Mercy Jimenez: Should add Mathieu only thing I dislike about FLY= low volume liquidity; I watch closely 4bigger bid/ask spreads/swings during mkt meltdowns
-
Mathieu Malecot: just stock talk any crazy action. nice divy, good management team that's already been tested = win
-
- View all 6 replies
-
-
Hillbilly Stock Star: One warning though may adjust weightings and hold positions very long time 3-5 years!
-
- View all 4 replies
-
The Hammer: owned pfe 7 years reinvest every divie hehehehe. if starts to breakout new highs and xtended will finally pull plug on some teva better imo. -
-
Joseph P. Porter
So much for that. AGNC down $.29, all REITs down. My bioPharms both up (PFE & CUR). Too bad BioPharms don't pay big divs. - View all 2 replies
-
wallstreetpro2: yep all my reit went down to NYMT ARR MTGE AGNC usually in bad tape they been going up -
-
- View all 6 replies
-
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
DAG1996: its the one i've had the hardest time averaging into this year because it just won't stop going up and won't pull back more than a point
-
Jacob Wolinsky
Johnson & Johnson: Why Value Investors Should be Looking http://bit.ly/M6zDRh $JNJ $NVS $AZN $BMY $PFE $GS - View all 1 replies
-
-
- View all 9 replies
-
DAG1996: plus, i average in to all holdings so it doesn't mater if i time the bottoms exactly right, which i consider impossible anyway
-